Apeloa Pharmaceutical Co.,Ltd.(000739),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000739 Apeloa Pharmaceutical Co.,Ltd.

Closed 10-22 15:00:00

20.88

-0.30

-1.42%

High21.43	Low20.38	Vol12.77M
Open21.19	D1 Closing21.18	Amplitude4.96%
Mkt Cap24.18B	Tradable Cap24.18B	Total Shares1.16B
T/O266.00M	T/O Rate1.10%	Tradable Shares1.16B
P/B3.74	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"Apeloa Pharmaceutical Co.,Ltd.","latestPrice":20.88,"timestamp":1792652598000,"preClose":21.18,"halted":0,"volume":12767838,"delay":0,"changeRate":-0.0142,"floatShares":1158000000,"shares":1158000000,"eps":0.7338,"marketStatus":"Closed","change":-0.3,"latestTime":"10-22 15:00:00","open":21.19,"high":21.43,"low":20.38,"amount":266000000,"amplitude":0.0496,"askPrice":20.9,"askSize":10,"bidPrice":20.88,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.7338,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.18,"symbolType":"stock","openAndCloseTimeList":[[1792632600000,1792639800000],[1792645200000,1792652400000]],"highLimit":23.3,"lowLimit":19.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":3.74,"roa":"--","peRate":28.45462,"roe":"8.05%","epsLYR":0.7723,"committee":0.386301,"marketValue":24188000000,"turnoverRate":0.011,"status":1,"floatMarketCap":24179000000},"requestUrl":"/m/hq/s/000739/tweets","defaultTab":"tweets","newsList":[{"id":"2674691834","title":"Apeloa Pharmaceutical Subsidiary Secures Marketing Approval for Prostate Cancer Drug API","url":"https://stock-news.laohu8.com/highlight/detail?id=2674691834","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674691834?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:04","pubTimestamp":1791533072,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical  said its subsidiary Zhejiang Progen Jiayuan Pharmaceutical has received marketing approval from China's National Medical Products Administration.The approval covers its deutenzalutamide active pharmaceutical ingredient for prostate cancer treatment, according to a Friday Shenzhen bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","OTX.SI","BK0060","LU2148510915.USD","BK0239","LU1064130708.USD","000739","BK0188","BK6100","BK6520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142282527","title":"Apeloa Pharmaceutical's Deuterated Enzalutamide API Receives Marketing Approval for Chemical Drug Substance Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1142282527","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142282527?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:50","pubTimestamp":1791456625,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) has announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received a Chemical Drug Substance Marketing...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU1064130708.USD","IPOS","000739","LU2148510915.USD","BK0239","BK0060","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194782083","title":"Apeloa Pharmaceutical's Wholly Owned Unit Gains Approval for Deuterated Enzalutamide API Marketing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1194782083","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194782083?lang=en_us&edition=fundamental","pubTime":"2026-10-08 17:50","pubTimestamp":1791453023,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739) has announced that its wholly owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., has received a Notice of Approval for the Marketing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","LU2148510915.USD","BK0060","IPOS","000739","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668995965","title":"Apeloa Honored with Frost & Sullivan's 2026 Global CDMO Company of the Year Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995965","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995965?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:59","pubTimestamp":1789639140,"startTime":"0","endTime":"0","summary":"Global GIL Recognition Spotlights Apeloa’s End-to-End \"API + Drug Product\" Integration, Advanced Technology Platforms, and Its Compliance Track Record in Regulated MarketsSHANGHAI, Sept.  17, 2026 (GL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/17/3363781/0/en/apeloa-honored-with-frost-sullivan-s-2026-global-cdmo-company-of-the-year-award.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","EES","000739","ADC","GIL","BK4231","BK0239","BK4139","BK0060","BK0188","BK4202","CDMO","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617885","title":"Apeloa Pharmaceutical Subsidiary Gets US Abbreviated Drug Approval for Anti-Epileptic Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617885","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617885?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:45","pubTimestamp":1789458328,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Apeloa Pharmaceutical  subsidiary Zhejiang Apeloa Jutai Pharmaceutical's abbreviated new drug application for its brivaracetam tablets, according to a Tuesday filing with the Shenzhen bourse.The drug is indicated for epilepsy-related partial-onset seizures, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000739","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123614423","title":"Apeloa Pharma's Subsidiary Secures FDA Nod for Brivaracetam Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1123614423","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123614423?lang=en_us&edition=fundamental","pubTime":"2026-09-14 16:58","pubTimestamp":1789376302,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) has announced that its wholly-owned subsidiary, Zhejiang Apeloa Jutai Pharmaceutical Co., Ltd. (\"Jutai Pharma\"), has received notification from the U.S....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000739","BK4585","LABU","BK4588","BK0239","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552475","title":"Apeloa Pharmaceutical Gets China Marketing Nod for Anti-Infection API","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552475","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666552475?lang=en_us&edition=fundamental","pubTime":"2026-09-10 12:35","pubTimestamp":1789014946,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical  unit Zhejiang Apeloa Tobang Pharmaceutical obtained marketing approval from China's drug regulator for the active pharmaceutical ingredient cefditoren pivoxil.The API is used to treat respiratory, urinary, biliary, skin and soft tissue infections, as well as obstetric, gynecological, ophthalmic and dental infections, according to a Thursday filing with the Shenzhen bourse.Shares of the pharmaceutical company slid 1% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6520","BK0060","BK0188","BK6100","OTX.SI","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155717358","title":"Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1155717358","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155717358?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:50","pubTimestamp":1788947414,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","IPOS","BK0060","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123195228","title":"Apeloa Pharmaceutical's Pentoxifylline Extended-Release Tablets Secure Official Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195228","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123195228?lang=en_us&edition=fundamental","pubTime":"2026-08-10 16:29","pubTimestamp":1786350579,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) announced that its controlling subsidiary, Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from the National...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000739","BK0060","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657504407","title":"Apeloa Pharmaceutical's Unit Gets Nod to Market Fulzerasib API","url":"https://stock-news.laohu8.com/highlight/detail?id=2657504407","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657504407?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:53","pubTimestamp":1785995588,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical's  unit, Zhejiang Apeloa Jiayuan Pharmaceutical, received approval from China's National Medical Products Administration for the marketing of an active pharmaceutical ingredient for Fulzerasib, according to a Thursday.The drug is used for the treatment of adults with advanced KRAS G12C-mutant non-small cell lung cancer.The Chinese pharmaceutical company's shares fell 2% during the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK6520","BK6100","BK0239","000739","OTX.SI","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141008888","title":"Apeloa Pharmaceutical Subsidiary Gains Approval for Fuzereisai Active Ingredient Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1141008888","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141008888?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:16","pubTimestamp":1785924992,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., has received the \"Chemical Bulk Drug Listing Application...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0060","BK0188","000739","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656584761","title":"Apeloa Pharmaceutical Partners with Jitai Technology for CDMO Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2656584761","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656584761?lang=en_us&edition=fundamental","pubTime":"2026-08-04 13:09","pubTimestamp":1785820189,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical  signed a strategic cooperation framework agreement with Jitai Technology Beijing to collaborate on contract development and manufacturing organization  services and related projects.The five-year partnership positions Apeloa as the preferred CDMO provider for Jitai and its affiliates, while exploring new project companies and joint investments, according to a Tuesday filing with the Shenzhen bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000739","BK4139","BK0239","CDMO","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655668851","title":"Apeloa Pharmaceutical Unit Wins China Approval for Levocarnitine Oral Solution; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655668851","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655668851?lang=en_us&edition=fundamental","pubTime":"2026-07-29 14:24","pubTimestamp":1785306294,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical's  unit Zhejiang Apeloa Kangyu Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its levocarnitine oral solution, according to a Shenzhen bourse filing on Wednesday.The drug is used to treat primary systemic carnitine deficiency and secondary carnitine deficiency.The pharmaceutical company's shares jumped 5% during the afternoon trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000739","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152689879","title":"Apeloa Pharmaceutical Unit Secures Drug Registration Certificate for Levocarnitine Oral Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=1152689879","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152689879?lang=en_us&edition=fundamental","pubTime":"2026-07-28 17:38","pubTimestamp":1785231511,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (Shenzhen: 000739) has announced that its controlling subsidiary, Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., has obtained a Drug Registration Certificate from the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","000739","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654073066","title":"Apeloa Pharmaceutical Unit Signs Cooperation Agreement With Two Biotech Firms; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654073066","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654073066?lang=en_us&edition=fundamental","pubTime":"2026-07-28 13:42","pubTimestamp":1785217362,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical's  subsidiary, Zhejiang Ante Yutai Biotechnology, entered into a cooperation agreement with Shanghai Wuxi Biologics and Shanghai Duoning Biotechnology, according to a Shenzhen bourse filing on Tuesday.Under the deal, Wuxi Biologics will provide research, development and manufacturing services to Ante Yutai.Duoning Biotech will also provide key consumables and supporting hardware to Ante Yutai for biologics research and development, and manufacturing.The pharmaceutical company's shares fell 3% during the afternoon trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK4581","XBI","BK4585","BK4588","000739","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653711604","title":"Apeloa Pharmaceutical Obtains EU Certificate for Gabapentin; Shares Down 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653711604","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653711604?lang=en_us&edition=fundamental","pubTime":"2026-07-23 14:26","pubTimestamp":1784787978,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical  obtained a certificate of suitability from the European Union for the gabapentin active pharmaceutical ingredient, according to a Shenzhen bourse filing on Thursday.The drug is used for the treatment of postherpetic neuralgia in adults and epilepsy in children.The pharmaceutical company's shares fell nearly 2% during the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LNGR","IEIH","BK4156","BK0060","BK0188","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113378346","title":"Apeloa Pharmaceutical's Subsidiary Secures European CEP for Gabapentin API","url":"https://stock-news.laohu8.com/highlight/detail?id=1113378346","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113378346?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:24","pubTimestamp":1784726656,"startTime":"0","endTime":"0","summary":"An announcement from Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) reveals that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., has recently received a Certificate of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","000739","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652158406","title":"Apeloa Pharmaceutical to Set Up 10 Million Yuan Joint Venture","url":"https://stock-news.laohu8.com/highlight/detail?id=2652158406","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652158406?lang=en_us&edition=fundamental","pubTime":"2026-07-17 16:48","pubTimestamp":1784278111,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical  plans to establish a joint venture with three other investors, according to a Shenzhen bourse filing on Friday.The venture, Zhejiang Ante Yutai Biotechnology, will manufacture antibody and protein drugs, and other biopharmaceutical products and will have a registered capital of 10 million yuan.The company will own 34.6% of the venture.The pharmaceutical company's shares slumped 6% at the close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000739","BK4185","BK0188","BK0239","BK0060","JYNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172834074","title":"Apeloa Pharmaceutical to Form Joint Venture with Related Parties for Biopharmaceutical Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1172834074","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172834074?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:34","pubTimestamp":1784198077,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (SHE: 000739) has announced plans to establish a joint venture with related parties, aiming to foster the long-term development of its core business, expand its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","BK0060","159839","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148714808","title":"Apeloa Pharmaceutical's Subsidiary Secures Drug Registration Certificate for Sodium Valproate Sustained-Release Tablets (I)","url":"https://stock-news.laohu8.com/highlight/detail?id=1148714808","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148714808?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:06","pubTimestamp":1782302786,"startTime":"0","endTime":"0","summary":"In a recent announcement, Apeloa Pharmaceutical Co.,Ltd. (SHE: 000739) disclosed that its subsidiary, Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0060","BK0188","000739"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792653551301,"stockEarnings":[{"period":"1week","weight":-0.1387},{"period":"1month","weight":-0.1425},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.341},{"period":"ytd","weight":0.3245}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":-0.06},{"period":"3month","weight":-0.0422},{"period":"6month","weight":-0.0899},{"period":"1year","weight":-0.0519},{"period":"ytd","weight":-0.0645}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36793人(较上一季度增加9.11%)","perCapita":"31473股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":"　　普洛药业股份有限公司的主营业务是创新药研发生产服务（CDMO）、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是原料药中间体、创新药研发生产服务、药品。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apeloa Pharmaceutical Co.,Ltd.(000739),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apeloa Pharmaceutical Co.,Ltd.(000739) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apeloa Pharmaceutical Co.,Ltd.,000739,Apeloa Pharmaceutical Co.,Ltd.股票,Apeloa Pharmaceutical Co.,Ltd.股票老虎,Apeloa Pharmaceutical Co.,Ltd.股票老虎国际,Apeloa Pharmaceutical Co.,Ltd.行情,Apeloa Pharmaceutical Co.,Ltd.股票行情,Apeloa Pharmaceutical Co.,Ltd.股价,Apeloa Pharmaceutical Co.,Ltd.股市,Apeloa Pharmaceutical Co.,Ltd.股票价格,Apeloa Pharmaceutical Co.,Ltd.股票交易,Apeloa Pharmaceutical Co.,Ltd.股票购买,Apeloa Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apeloa Pharmaceutical Co.,Ltd.(000739),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apeloa Pharmaceutical Co.,Ltd.(000739) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction